Risk factors in patients with herpes zoster infections: case-control study

• Authors: Maja Pezer , Vjeran Vidić , Jadranka Nikolić , Ivo Curić , Jurica Arapović
• Languages of publication: EN

Abstracts

EN

The aim of this study was to determine the prevalence of chronic disease and the risk factors for herpes zoster infection. In this case-control study medical records were collected from 55 patients who presented with herpes zoster and 54 patients in a control group who presented with gastroenterocolitis. Both groups were treated at the Clinic for Infectious Diseases, University Clinical Hospital Mostar from January, 2005 to December, 2010. When we compared the herpes zoster group with the control group, we did not demonstrate any significant difference in the overall prevalence of chronic diseases. However, the prevalence of diabetes and cancer was statistically higher when compared to the control group. A statistically significant difference in the number of cigarette smokers was not observed, whereas the number who consumed alcohol in the herpes zoster group was significantly higher compared to the control group. The correlation between alcohol and herpes zoster could help in solving the reactivation mechanism of VZV.

Keywords

EN

Varicella-zoster virus; Herpes zoster; Prevalence; Risk factors; Chronic diseases; Alcoholism

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 4
• Pages: 493-498

Dates

published

1 - 8 - 2013

online

12 - 6 - 2013

Contributors

author

Maja Pezer

• Faculty of Medicine, University of Mostar, Bijeli Brijeg b.b., 88000, Mostar, Bosnia and Herzegovina

author

Vjeran Vidić

• Faculty of Medicine, University of Mostar, Bijeli Brijeg b.b., 88000, Mostar, Bosnia and Herzegovina

author

Jadranka Nikolić

author

Ivo Curić

author

Jurica Arapović

References

• [1] Cohen J.I., The varicella-zoster virus genome, Curr Top Microbiol Immunol, 2010, 342, 1–14 DOI: 10.1007/82_2010_10 http://dx.doi.org/10.1007/82_2010_10[Crossref]
• [2] Seward J., Jumaan A., VSV: persistence in the population, In: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P. S., Roizman B., Whitley R. et al. (Eds), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge: Cambridge University Press, 2007
• [3] Moffat J., Ku C.C., Zerboni L., Sommer M., Arvin A., VZV: pathogenesis and the disease consequences of primary infection, In: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P. S., Roizman B., Whitley R. et al. (Eds), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge: Cambridge University Press, 2007
• [4] Liesegang T.J., Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity, Ophthalmology, 2008, 115, S3–12 DOI: 10.1016/j.ophtha.2007.10.009 http://dx.doi.org/10.1016/j.ophtha.2007.10.009[Crossref][WoS]
• [5] Arvin A., Abendroth A., VZV: immunobiology and host response, In: Arvin A., Campadelli-Fiume G., Mocarski E., Moore P. S., Roizman B., Whitley R. et al. (Eds), Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Cambridge: Cambridge University Press 2007
• [6] Brisson M., Edmunds W.J., Law B., Gay N.J., Walld R., Brownell M., et al., Epidemiology of varicella zoster virus infection in Canada and the United Kingdom, Epidemiol Infect, 2001, 127, 305–314 http://dx.doi.org/10.1017/S0950268801005921[WoS]
• [7] Glynn C., Crockford G., Gavaghan D., Cardno P., Price D., Miller J., Epidemiology of shingles, J R Soc Med, 1990, 83, 617–619
• [8] Wareham D.W., Breuer J., Herpes zoster, BMJ, 2007, 334, 1211–1215 DOI: 10.1136/bmj.39206.571042.AE http://dx.doi.org/10.1136/bmj.39206.571042.AE[Crossref]
• [9] Liesegang T.J., Herpes zoster virus infection, Curr Opin Ophthalmol, 2004, 15, 531–536 http://dx.doi.org/10.1097/01.icu.0000143686.68103.46
• [10] van Wijck A.J., Wallace M., Mekhail N., van Kleef M., Evidence-based interventional pain medicine according to clinical diagnoses. 17. Herpes zoster and post-herpetic neuralgia, Pain Pract, 2011, 11, 88–97 DOI: 10.1111/j.1533-2500.2010.00428.x http://dx.doi.org/10.1111/j.1533-2500.2010.00428.x[Crossref]
• [11] Chidiac C., Bruxelle J., Daures J.P., Hoang-Xuan T., Morel P., Leplege A., et al., Characteristics of patients with herpes zoster on presentation to practitioners in France, Clin Infect Dis, 2001, 33, 62–69 DOI: 10.1086/320884 http://dx.doi.org/10.1086/320884[Crossref]
• [12] Thomas S.L., Hall A.J., What does epidemiology tell us about risk factors for herpes zoster?, Lancet Infect Dis, 2004, 4, 26–33 http://dx.doi.org/10.1016/S1473-3099(03)00857-0
• [13] Leung J., Harpaz R., Baughman A.L., Heath K., Loparev V., Vazquez M., et al., Evaluation of laboratory methods for diagnosis of varicella, Clin Infect Dis, 2010, 51, 23–32 DOI: 10.1086/653113 http://dx.doi.org/10.1086/653113[Crossref]
• [14] Opstelten W., Eekhof J., Neven A.K., Verheij T., Treatment of herpes zoster, Can Fam Physician, 2008, 54, 373–377
• [15] Alper B.S., Lewis P.R., Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?, J Fam Pract, 2000, 49, 255–264
• [16] Lancaster T., Silagy C., Gray S., Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials, Br J Gen Pract, 1995, 45, 39–45
• [17] Wood M.J., Johnson R.W., McKendrick M.W., Taylor J., Mandal B.K., Crooks J., A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster, N Engl J Med, 1994, 330, 896–900 DOI: 10.1056/NEJM199403313301304 http://dx.doi.org/10.1056/NEJM199403313301304[Crossref]
• [18] Berry J.D., Petersen K.L., A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster, Neurology, 2005, 65, 444–447 DOI: 10.1212/01.wnl.0000168259.94991.8a http://dx.doi.org/10.1212/01.WNL.0000168259.94991.8a[Crossref]
• [19] Schmader K., Herpes zoster in older adults, Clin Infect Dis, 2001, 32, 1481–1486 DOI: 10.1086/320169 http://dx.doi.org/10.1086/320169[Crossref]
• [20] Schmader K., George L.K., Burchett B.M., Pieper C.F., Hamilton J.D., Racial differences in the occurrence of herpes zoster, J Infect Dis, 1995, 171, 701–704 http://dx.doi.org/10.1093/infdis/171.3.701
• [21] Okamoto S., Hata A., Sadaoka K., Yamanishi K., Mori Y., Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals, J Infect Dis, 2009, 200, 1606–1610 DOI: 10.1086/644646 http://dx.doi.org/10.1086/644646[WoS][Crossref]
• [22] Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C., et al., Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents, JAMA, 2009, 301, 737–744 DOI: 10.1001/jama.2009.146 http://dx.doi.org/10.1001/jama.2009.146[Crossref]
• [23] Schuchter L.M., Wingard J.R., Piantadosi S., Burns W.H., Santos G.W., Saral R., Herpes zoster infection after autologous bone marrow transplantation, Blood, 1989, 74, 1424–1427
• [24] Toyama N., Shiraki K., Society of the Miyazaki Prefecture D., Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture, J Med Virol, 2009, 81, 2053–2058 DOI: 10.1002/jmv.21599 http://dx.doi.org/10.1002/jmv.21599[Crossref]
• [25] Joesoef R.M., Harpaz R., Leung J., Bialek S.R., Chronic medical conditions as risk factors for herpes zoster, Mayo Clinic proceedings Mayo Clinic, 2012, 87, 961–967 DOI: 10.1016/j.mayocp.2012.05.021 http://dx.doi.org/10.1016/j.mayocp.2012.05.021[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-013-0155-8